Previous close | 1.5100 |
Open | 1.5000 |
Bid | 1.4400 x 100 |
Ask | 1.4800 x 500 |
Day's range | 1.4309 - 1.5100 |
52-week range | 1.4309 - 9.7660 |
Volume | |
Avg. volume | 168,438 |
Market cap | 61.483M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.5900 |
Earnings date | 08 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 9.00 |
CARISMA THERAP (CARM) delivered earnings and revenue surprises of -24.32% and 12.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended March 31, 2024, and highlighted recent business updates.
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced new data demonstrating preclinical proof of concept using engineered anti-fibrotic macrophages for the treatment of liver fibrosis. The data was presented in a poster session at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting on May 8, 2024, in Baltimore, MD.